PAVmed Inc. announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study. This is the Company's first report of prospective data from multiple physicians demonstrating real-world clinical utility of EsoGuard® Esophageal DNA testing for the detection of esophageal precancer; and supplements its recently released positive data from a retrospective analysis of EsoGuard's clinical utility in firefighters. The study documents near perfect concordance, including 100% concordance in EsoGuard-positive patients, between clinically-directed EsoGuard test results and subsequent medical decision-making by multiple different prescribing physicians.

It demonstrates that EsoGuard allows physicians to appropriately triage those requiring confirmatory endoscopy in a manner broadly consistent with established, and recently updated, professional society guidelines. The manuscript reports on the first 275 patients at-risk for esophageal precancer enrolled in the prospective multicenter CLUE study at four U.S. sites. 264 patients underwent successful nonendoscopic esophageal cell sampling using Lucid's EsoCheck® Cell Collection Device?a 96% technical success rate.

Of the 232 patients for whom results were available 220 had sufficient DNA (95%) for EsoGuard testing. The prescribing physician referred all 68 patients with positive EsoGuard results (29%) for confirmatory endoscopy. 151 of the 152 patients with negative EsoGuard results were not referred for endoscopy.

One EsoGuard-negative patient was referred for endoscopy as part of a surgical evaluation, not for precancer screening. These results document 100% concordance between a positive EsoGuard test result and subsequent physician medical decision-making, and a 99% concordance with a negative result. EsoGuard eliminated the need for over one-hundred fifty costly, invasive, and inconvenient endoscopies at the four practices, consistent with professional society guidelines.